A method for extracting human antithrombin III from plasma
Through DEAE Sephadex A-50 gel adsorption, polyethylene glycol purification and heparin affinity chromatography, combined with appropriate buffer solution and stabilizer treatment, the problem of industrial extraction of human antithrombin III in the prior art was solved. It realizes an efficient, stable and safe preparation process and is suitable for industrial production.
Patent Information
- Application Number
- CN202110946978.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-02-24
AI Technical Summary
The prior art is difficult to efficiently extract human antithrombin III on an industrial scale, resulting in complex preparation processes, low harvesting rates and failure to achieve processes suitable for industrial production.
DEAE Sephadex A-50 gel adsorption, polyethylene glycol purification treatment, heparin affinity chromatography, paste virus inactivation, ultrafiltration concentration, sterilization filtration and nanomembrane virus removal filtration, etc., combined with appropriate buffer and stabilizer treatment to form an efficient process flow to extract human antithrombin III.
The high purity, stability and virus inactivation effect of human antithrombin III are achieved, which reduces labor intensity and equipment requirements, and improves preparation efficiency and safety.
Smart Images

Figure FT_1
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biopharmaceuticals, relates to an extraction process for blood products, and particularly relates to a method for extracting human antithrombin III. Background Art
[0002] Human antithrombin III (AT-III) is an important factor that controls the physiological coagulation reaction process and plays an anticoagulant role. It is mainly present in the human plasma system. The AT-III content in normal human plasma is 180-300 mg / L. It is mainly synthesized in the liver and can also be synthesized in vascular endothelial cells. AT-III is a potent natural anticoagulant and serine protease inhibitor that can inactivate multiple enzymes in the coagulation cascade reaction. It mainly works by inhibiting thrombin and FXa, and can also work by inhibiting FIXa, FXIa, FXIIa and plasmin. AT-III can play an anticoagulant role alone in the absence of heparin, and in the presence of heparin, AT-III can combine with heparin to form a complex, and its speed of inactivating thrombin and FXa can be increased by 1000-3500 times.
[0003] AT-III molecule is a single-chain glycoprotein, composed of 432 amino acid residues, with a molecular weight of 58,000 Da, containing 3 disulfide groups and 4 oligosaccharide groups, which are respectively attached to Asn at positions 96, 135, 155, and 192 of the peptide chain. Its protein structure is as follows: Figure 1 About 10% of plasma-derived AT-III molecules are subglycosylated AT-III (β-AT-III), whose peptide chain Asn 155 The isoelectric point of AT-III is pI = 4.8, and the average half-life in vivo is 3 days.
[0004] As a key substance in plasma that inhibits coagulation, the main physiological function of AT-III is to participate in maintaining normal anticoagulation function in the body and maintain the dynamic balance between the fibrinolytic system and the coagulation system. The anticoagulant effect it exerts accounts for about 80% of the total anticoagulant effect in the body. It is the most important anticoagulant component in the human body. When the activity of AT-III decreases, such as when it is lower than 70% of the normal level, the risk of thrombosis can be significantly increased. In 1965, Egeberg first reported familial thrombosis (ThromboPhi1ia) caused by hereditary AT-III deficiency, and initially clarified the relationship between AT-III deficiency and thrombosis tendency. Therefore, AT-III products are mainly used in the clinic to treat AT-III deficiency, which is divided into hereditary and acquired types.
[0005] The initial preparation of human antithrombin III preparations used adsorption with alumina, calcium phosphate, molecular sieve filtration, ion exchange chromatography and other means, which was not only time-consuming and labor-intensive, but also had a low yield of the product. In 1968, the average yield of ATⅢ first purified by Abildgaard was only 2%. In 1974, Miller-Andersson et al. separated human antithrombin III from plasma using heparin-Sepharose affinity chromatography, and then filtered through DEAE-Sephadex chromatography and Sephadex G-200 gel filtration, with a yield of about 34%. This method has been regarded as a classic method; other methods are similar, but these methods are still subject to certain conditions for the large-scale industrial preparation of human antithrombin III.
[0006] In 1975, Thaler et al. reported a two-step separation method, i.e. affinity chromatography on heparin agar followed by polyethylene glycol (PEG) precipitation, or PEG precipitation followed by heparin-agar affinity chromatography, with an additional ammonium sulfate precipitation step to remove PEG and trace contaminants. The product was homogeneous as identified by SDS-PAGE, and the N2 terminal amino acid was histidine after analysis of the human ATⅢ terminal. The purified preparation has both progressive antithrombin activity and heparin cofactor activity, and can separate >1 g of antithrombin III from 10-20 L of plasma with a yield of 60%, and its specific activity is 550 times that of plasma. In 1979, Wicker et al. first described the industrial-scale preparation of antithrombin III concentrate for clinical use, the raw materials of which were Cohn component IV-1 discarded from industrial production or plasma after removal of cold precipitate and precipitation with 20% PEG. In 1985, Smith et al. developed a Pasteur-inactivated human antithrombin III concentrate for clinical use. The plasma from which the cryoprecipitate and prothrombin complex had been removed was adsorbed in batches on heparin-Sepharose, eluted with high salt concentration, inactivated by Pasteur method at 60°C for 10 h in the presence of citrate, desalted on Sephadex G-25 column, then sterilized, filtered and freeze-dried. The average yield of the seven batches of products prepared in this way was 269 U / kg plasma. All the finished products passed the conventional animal safety and pyrogen tests and have been successfully used to treat patients with hereditary ATⅢ deficiency.
[0007] Almost all methods for separating and purifying human antithrombin III use heparin affinity chromatography, so heparin affinity chromatography is a key step in the separation and purification of human antithrombin III. At present, such affinity media in China mainly rely on imports, are expensive, and the preparation method is confidential. There are reports in China that have studied affinity media. In 2002, Zhao Yingxin et al. used poly(glycidyl methacrylate) microspheres (PGMA) as a matrix and bonded heparin on its surface by reduction amination to obtain a high-efficiency affinity chromatography filler with heparin as a ligand. The affinity capacity of this filler for human antithrombin III is 1.2 mg / g, and the recovery rates of human antithrombin III and human serum albumin are 96.9% and 94.4%, respectively; the apparent dissociation constant between heparin and antithrombin III was determined by frontier chromatography and was 1.96×10 -5 mol / L, the filler can be used to directly separate antithrombin III preparations from human plasma.
[0008] In 2005, Mu Chenghua et al. used self-made agarose gel 6FF as the matrix and heparin as the ligand to prepare the heparin-agarose gel 6FF medium by the reductive amination method. They investigated the influencing factors of the heparin coupling reaction and optimized it. The heparin ligand content was 2.7 mg / ml. The prepared medium was used to separate antithrombin III from human plasma. The recovery rate of human antithrombin III activity calculated from plasma was 31.76%, which was comparable to the separation effect of the commercial Heparin-Sepharose CL-6B.
[0009] There are also several domestic companies that have conducted in-depth research on the separation and purification of human antithrombin III, and can achieve a purity of more than 85% at the laboratory level. However, due to the relatively late development of production research on human antithrombin III preparations in China, most of the research on human antithrombin III is still in the laboratory development stage, and there has been no report on obtaining new drug certificates and production approvals. The main reason is that the preparation process suitable for industrial scale has not been established. Therefore, how to transform laboratory research results into processes suitable for industrial production has become the key to industrial development.
[0010] The invention develops a new optimized process for extracting human antithrombin III, develops a preparation process of human antithrombin III suitable for industrial production scale, and has the characteristics of good stability, high purity and better virus inactivation effect. Summary of the invention
[0011] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and to provide a method for extracting human antithrombin III. The prepared human antithrombin III preparation has high purity, high stability and good virus inactivation effect.
[0012] In order to achieve the above object, the present invention adopts the following technical solutions:
[0013] A method for extracting human antithrombin III from plasma comprises the following steps:
[0014] (1) Removal of cryoprecipitate from fresh frozen human plasma: After the fresh frozen human plasma is thawed and mixed evenly, the cryoprecipitate is removed by a flow centrifuge to obtain the plasma supernatant after centrifugation;
[0015] (2) DEAE Sephadex A-50 gel adsorption: DEAE Sephadex A-50 gel is added to the plasma supernatant obtained in step (1). The amount of dry gel added is 0.5-1.5 g / kg of liquid. The dry gel is pre-swelled with hot water for injection at a temperature above 70°C, then cooled with cold water for injection at a temperature below 25°C, and finally balanced with an equilibrium buffer. Stir at an appropriate speed (to ensure that the gel is evenly mixed and distributed in the solution and not too fast) for 1.0-2.0 hours, and filter to obtain a filtrate. The gel can be stored and reused after regeneration.
[0016] (3) Polyethylene glycol (PEG-4000) purification treatment: the pH of the filtrate obtained in step (2) is adjusted to 6.0-7.0, 10%-20% (w / v) polyethylene glycol (PEG-4000) is added, the precipitate is removed by centrifugation to obtain a supernatant, and 20%-30% (w / v) polyethylene glycol (PEG-4000) is added to the obtained supernatant, and the precipitate is recovered by centrifugation;
[0017] (4) Affinity chromatography: The heparin affinity column is first fully equilibrated with an equilibration solution, the precipitate obtained in step (3) is dissolved with the equilibration solution, and then filtered with a 0.45 μm filter element before loading. After loading, 40 column volumes of the equilibration solution are first used, then 15 column volumes of the washing buffer are used, and finally, the column is eluted with an elution buffer, and the eluate is collected;
[0018] (5) Inactivation of Pasteurella virus: adding a stabilizer to the eluate obtained in step (4), adjusting the pH of the solution to 7.0-8.0, and placing the solution in an environment of 60° C. for 10 hours;
[0019] (6) Affinity chromatography: The heparin affinity column was first fully equilibrated with an equilibration solution, and the feed solution obtained in step (5) was filtered through a 0.45 μm filter element and then loaded. After loading, 40 column volumes of the equilibration solution were first used, and then 15 column volumes of the washing buffer were used. Finally, the column was eluted with an elution buffer and the eluate was collected;
[0020] (7) Ultrafiltration concentration: The eluate obtained in step (6) was concentrated using a 10KD ultrafiltration membrane, and then dialyzed 5-6 times with an equal volume of dialysate, and finally concentrated to a human antithrombin III titer of about 50 IU / mL;
[0021] (8) Sterile filtration: Sterile filter the product using a 0.22 μm filter element;
[0022] (9) Nano-membrane virus removal filtration: pre-filter with a 0.1 μm filter element, then filter with a 15 nm filter element for virus removal;
[0023] (10) Packaging;
[0024] (11) Freeze-drying: precooling, quick freezing, annealing, primary drying and secondary drying are performed to finally obtain human antithrombin III freeze-dried powder.
[0025] The DEAE Sephadex A-50 gel adsorption described in step (2) uses the company's plasma adsorption filtration device (Chinese invention patent CN201810248696.8 A plasma adsorption filtration device for the production of coagulation factor blood products).
[0026] The equilibration buffer described in step (2) is formulated as follows: 0.01-0.02 M sodium citrate, 0.15-0.25 M sodium chloride, and a pH of 7.0-8.0.
[0027] The formula of the balancing solution in the affinity chromatography described in step (4) is: 0.1-0.2M Tris-HCl, 0.01-0.02M trisodium citrate, 0.2-0.3M sodium chloride, pH 7.0-8.0, the formula of the washing buffer is: 0.1-0.2M Tris-HCl, 0.01-0.02M trisodium citrate, 0.3-0.4M sodium chloride, pH 7.0-8.0, and the formula of the elution buffer is: 0.1-0.2M Tris-HCl, 0.01-0.02M trisodium citrate, 1.5-2.5M sodium chloride, pH 7.0-8.0.
[0028] The stabilizer formula of step (5) is: 5%-10% sodium citrate, 1.5-2.5M sodium chloride, 50-60% (w / v) sorbitol, pH 7.0-8.0.
[0029] The dialysate formula described in step (7) is: glycine: 1-4% (w / w), pH: 7.0-8.0, liquid temperature: room temperature.
[0030] Advantages of the present invention:
[0031] (1) DEAE Sephadex A-50 gel adsorption, the pilot scale uses our company's plasma adsorption filtration device (Chinese invention patent CN201810248696.8 A plasma adsorption filtration device for the production of coagulation factor blood products). It can realize the automatic filtration and collection of gel in a streamlined manner, greatly reducing the labor intensity of the staff. At the same time, the pressure difference is stable and controllable during the entire filtration process, which plays a good protective role for the subsequent coagulation factor components and gel particles, and is suitable for industrial production scale.
[0032] (2) The entire process involves only two chromatography systems, which reduces the number of chromatography systems and supporting facilities and sites compared to some existing processes with three-step chromatography.
[0033] (3) Compared with the combination of traditional S / D virus inactivation and ion exchange chromatography, the risk of introducing and removing residual Tween 80 and tributyl phosphate is eliminated. By adding a suitable stabilizer, the Pasteur virus inactivation method with relatively good virus inactivation effect is adopted.
[0034] (4) Use 15 nanometer nanofiltration to remove viruses, ensuring better virus filtration effect and higher safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 Human antithrombin III protein structure DETAILED DESCRIPTION
[0036] The present invention is further described in detail below with reference to examples, but the embodiments of the present invention are not limited thereto.
[0037] Example 1
[0038] (1) Removal of cryoprecipitate from fresh frozen human plasma: 500 L of fresh frozen human plasma was melted and mixed evenly, and then passed through a flow centrifuge to remove the cryoprecipitate, and the plasma supernatant was obtained after centrifugation;
[0039] (2) DEAE Sephadex A-50 gel adsorption: DEAE Sephadex A-50 gel is added to the plasma supernatant obtained in step (1). The amount of dry gel added is 500 g. The dry gel is pre-swelled with hot water for injection at a temperature above 70°C, and then cooled with cold water for injection at a temperature below 25°C. Finally, the dry gel is balanced with an equilibrium buffer and stirred at an appropriate speed (to ensure that the gel is evenly mixed and distributed in the solution and not too fast) for 1.0 hour. The filtrate is filtered and the gel is regenerated and stored for repeated use. The equilibrium buffer formula is: 0.02 M sodium citrate, 0.2 M sodium chloride, pH 7.0
[0040] (3) Polyethylene glycol (PEG-4000) purification treatment: the pH of the filtrate obtained in step (2) was adjusted to 6.5, 10% (w / v) polyethylene glycol (PEG-4000) was added, the precipitate was removed by centrifugation to obtain a supernatant, and 20% (w / v) polyethylene glycol (PEG-4000) was added to the obtained supernatant, and the precipitate was recovered by centrifugation;
[0041] (4) Affinity chromatography: The heparin affinity column was first fully equilibrated with an equilibration solution, the precipitate obtained in step (3) was dissolved with the equilibration solution, and then filtered with a 0.45 μm filter element before loading. After loading, 40 column volumes of the equilibration solution were first used, and then 15 column volumes of the washing buffer were used. Finally, the column was eluted with an elution buffer, and the eluate was collected. The equilibration solution formula was: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 0.2 M sodium chloride, pH 7.0, the washing buffer formula was: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 0.3 M sodium chloride, pH 7.0, and the elution buffer formula was: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 1.5 M sodium chloride, pH 7.0.
[0042] (5) Inactivation of Pasteurella virus: Add a stabilizer to the eluate obtained in step (4), then adjust the pH of the solution to 7.0, and place the solution in a 60° C. environment for 10 hours; the stabilizer formula is: 5% sodium citrate, 1.5M sodium chloride, 50% (w / v) sorbitol, pH 7.0.
[0043] (6) Affinity chromatography: The heparin affinity column is first fully equilibrated with an equilibration solution, and the feed solution obtained in step (5) is filtered through a 0.45 μm filter element and then loaded. After loading, the column is first flushed with the equilibration solution for 40 column volumes, then flushed with the washing buffer for 15 column volumes, and finally eluted with the elution buffer, and the eluate is collected; the equilibration solution formula is: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 0.2 M sodium chloride, pH 7.0, the washing buffer formula is: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 0.3 M sodium chloride, pH 7.0, and the elution buffer formula is: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 1.5 M sodium chloride, pH 7.0.
[0044] (7) Ultrafiltration concentration: The eluate obtained in step (6) is concentrated using a 10KD ultrafiltration membrane, and then dialyzed 6 times with an equal volume of dialysate, and finally concentrated to a human antithrombin III titer of about 50 IU / mL; the dialysate formula is: glycine: 1% (w / w), pH: 7.0, liquid temperature: room temperature.
[0045] (8) Sterile filtration: Sterile filter the product using a 0.22 μm filter element;
[0046] (9) Nano-membrane virus removal filtration: pre-filter with a 0.1 μm filter element, then filter with a 15 nm filter element for virus removal;
[0047] (10) Packaging;
[0048] (11) Freeze-drying: precooling, quick freezing, annealing, primary drying and secondary drying are performed to finally obtain human antithrombin III freeze-dried powder.
[0049] Example 2
[0050] (1) Removal of cryoprecipitate from fresh frozen human plasma: 800 L of fresh frozen human plasma was melted and mixed evenly, and then passed through a flow centrifuge to remove the cryoprecipitate, and the plasma supernatant was obtained after centrifugation;
[0051] (2) DEAE Sephadex A-50 gel adsorption: DEAE Sephadex A-50 gel was added to the plasma supernatant obtained in step (1). The amount of dry gel added was 960 g. The dry gel was pre-swollen with hot water for injection at a temperature above 70°C, then cooled with cold water for injection at a temperature below 25°C, and finally balanced with an equilibrium buffer. Stirring was performed at an appropriate speed (to ensure that the gel was evenly mixed and distributed in the solution and not too fast) for 1.5 hours, and the filtrate was filtered. The gel was regenerated and stored for repeated use. The equilibrium buffer formula was: 0.015 M sodium citrate, 0.2 M sodium chloride, pH 7.5
[0052] (3) Polyethylene glycol (PEG-4000) purification treatment: the pH of the filtrate obtained in step (2) was adjusted to 6.5, 15% (w / v) polyethylene glycol (PEG-4000) was added, the precipitate was removed by centrifugation to obtain a supernatant, and 25% (w / v) polyethylene glycol (PEG-4000) was added to the obtained supernatant, and the precipitate was recovered by centrifugation;
[0053] (4) Affinity chromatography: The heparin affinity column is first fully equilibrated with an equilibration solution, and the precipitate obtained in step (3) is dissolved with the equilibration solution, and then filtered with a 0.45 μm filter element before loading. After loading, 40 column volumes of the equilibration solution are first used, and then 15 column volumes of the washing buffer are used, and finally the elution is performed with an elution buffer, and the eluate is collected; the equilibration solution formula is: 0.15 M Tris-HCl, 0.01 M trisodium citrate, 0.2 M sodium chloride, pH 7.5, the washing buffer formula is: 0.15 M Tris-HCl, 0.01 M trisodium citrate, 0.3 M sodium chloride, pH 7.5, and the elution buffer formula is: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 1.5 M sodium chloride, pH 7.5.
[0054] (5) Inactivation of Pasteurella virus: Add a stabilizer to the eluate obtained in step (4), then adjust the pH of the solution to 7.5, and place the solution in a 60° C. environment for 10 hours; the stabilizer formula is: 8% sodium citrate, 2.0 M sodium chloride, 55% (w / v) sorbitol, pH 7.5.
[0055] (6) Affinity chromatography: The heparin affinity column is first fully equilibrated with an equilibration solution, and the feed solution obtained in step (5) is filtered through a 0.45 μm filter element and then loaded. After loading, the column is first flushed with the equilibration solution for 40 column volumes, then flushed with the washing buffer for 15 column volumes, and finally eluted with the elution buffer, and the eluate is collected; the equilibration solution formula is: 0.15 M Tris-HCl, 0.01 M trisodium citrate, 0.2 M sodium chloride, pH 7.5, the washing buffer formula is: 0.15 M Tris-HCl, 0.01 M trisodium citrate, 0.3 M sodium chloride, pH 7.5, and the elution buffer formula is: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 1.5 M sodium chloride, pH 7.5.
[0056] (7) Ultrafiltration concentration: The eluate obtained in step (6) is concentrated using a 10KD ultrafiltration membrane, and then dialyzed 6 times with an equal volume of dialysate, and finally concentrated to a human antithrombin III titer of about 50 IU / mL; the dialysate formula is: glycine: 3% (w / w), pH: 7.0, liquid temperature: room temperature.
[0057] (8) Sterile filtration: Sterile filter the product using a 0.22 μm filter element;
[0058] (9) Nano-membrane virus removal filtration: pre-filter with a 0.1 μm filter element, then filter with a 15 nm filter element for virus removal;
[0059] (10) Packaging;
[0060] (11) Freeze-drying: precooling, quick freezing, annealing, primary drying and secondary drying are performed to finally obtain human antithrombin III freeze-dried powder.
[0061] Example 3
[0062] (1) Removal of cryoprecipitate from fresh frozen human plasma: 1000 L of fresh frozen human plasma was melted and mixed evenly, and then passed through a flow centrifuge to remove the cryoprecipitate, and the plasma supernatant was obtained after centrifugation;
[0063] (2) DEAE Sephadex A-50 gel adsorption: DEAE Sephadex A-50 gel is added to the plasma supernatant obtained in step (1). The amount of dry gel added is 1500 g. The dry gel is pre-swelled with hot water for injection at a temperature above 70°C, then cooled with cold water for injection at a temperature below 25°C, and finally balanced with an equilibrium buffer. Stir at an appropriate speed (to ensure that the gel is evenly mixed and distributed in the solution and not too fast) for 2 hours, and filter to obtain the filtrate. The gel can be stored and reused after regeneration. The equilibrium buffer formula is: 0.015 M sodium citrate, 0.2 M sodium chloride, pH 7.5
[0064] (3) Polyethylene glycol (PEG-4000) purification treatment: the pH of the filtrate obtained in step (2) was adjusted to 6.5, 15% (w / v) polyethylene glycol (PEG-4000) was added, the precipitate was removed by centrifugation to obtain a supernatant, and 25% (w / v) polyethylene glycol (PEG-4000) was added to the obtained supernatant, and the precipitate was recovered by centrifugation;
[0065] (4) Affinity chromatography: The heparin affinity column is first fully equilibrated with an equilibration solution, and the precipitate obtained in step (3) is dissolved with the equilibration solution, and then filtered with a 0.45 μm filter element before loading. After loading, 40 column volumes of the equilibration solution are first used, and then 15 column volumes of the washing buffer are used, and finally the elution is performed with an elution buffer, and the eluate is collected; the equilibration solution formula is: 0.15 M Tris-HCl, 0.01 M trisodium citrate, 0.2 M sodium chloride, pH 7.5, the washing buffer formula is: 0.15 M Tris-HCl, 0.01 M trisodium citrate, 0.3 M sodium chloride, pH 7.5, and the elution buffer formula is: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 1.5 M sodium chloride, pH 7.5.
[0066] (5) Inactivation of Pasteurella virus: Add a stabilizer to the eluate obtained in step (4), then adjust the pH of the solution to 7.5, and place the solution in a 60° C. environment for 10 hours; the stabilizer formula is: 10% sodium citrate, 2.0 M sodium chloride, 55% (w / v) sorbitol, pH 7.5.
[0067] (6) Affinity chromatography: The heparin affinity column is first fully equilibrated with an equilibration solution, and the feed solution obtained in step (5) is filtered through a 0.45 μm filter element and then loaded. After loading, the column is first flushed with the equilibration solution for 40 column volumes, then flushed with the washing buffer for 15 column volumes, and finally eluted with the elution buffer, and the eluate is collected; the equilibration solution formula is: 0.15 M Tris-HCl, 0.01 M trisodium citrate, 0.2 M sodium chloride, pH 7.5, the washing buffer formula is: 0.15 M Tris-HCl, 0.01 M trisodium citrate, 0.3 M sodium chloride, pH 7.5, and the elution buffer formula is: 0.1 M Tris-HCl, 0.01 M trisodium citrate, 1.5 M sodium chloride, pH 7.5.
[0068] (7) Ultrafiltration concentration: The eluate obtained in step (6) is concentrated using a 10KD ultrafiltration membrane, and then dialyzed 6 times with an equal volume of dialysate, and finally concentrated to a human antithrombin III titer of about 50 IU / mL; the dialysate formula is: glycine: 3% (w / w), pH: 7.0, liquid temperature: room temperature. After adjustment, the human antithrombin III specific activity of the feed liquid reaches 13 IU / mg protein.
[0069] (8) Sterile filtration: Sterile filter the product using a 0.22 μm filter element;
[0070] (9) Nano-membrane virus removal filtration: pre-filter with a 0.1 μm filter element, then filter with a 15 nm filter element for virus removal;
[0071] (10) Packaging;
[0072] (11) Freeze-drying: precooling, quick freezing, annealing, primary drying and secondary drying are performed to finally obtain human antithrombin III freeze-dried powder.
[0073] The above embodiment is only one of the preferred implementation modes of the present invention, and is not intended to limit the protection scope of the present invention. Therefore, any equivalent changes made according to the process of the present invention should be included in the protection scope of the present invention as long as they are within the scope of the gist of the present invention.
Claims
1. A method for extracting human antithrombin III from plasma, characterized in that The steps include: (1) Removal of cryoprecipitate from fresh frozen human plasma: After the fresh frozen human plasma is melted and mixed evenly, the cryoprecipitate is removed by a flow centrifuge to obtain the plasma supernatant after centrifugation; (2) DEAE Sephadex A-50 gel adsorption: DEAE Sephadex A-50 gel is added to the plasma supernatant obtained in step (1). The amount of dry gel added is 0.5-1.5 g / kg of liquid. The dry gel is pre-swelled with hot water for injection at a temperature above 70°C, and then cooled with cold water for injection at a temperature below 25°C. Finally, the dry gel is balanced with an equilibrium buffer and stirred at an appropriate speed for 1.0-2.0 hours to ensure that the gel is evenly mixed in the solution. The speed should not be too fast. The filtrate is filtered to obtain the filtrate. The gel can be stored and reused after regeneration. The equilibration buffer formula is: 0.01-0.02M sodium citrate, 0.15-0.25M sodium chloride, pH 7.0-8.0; (3) Polyethylene glycol (PEG-4000) purification treatment: the pH of the filtrate obtained in step (2) is adjusted to 6.0-7.0, 10%-20% (w / v) polyethylene glycol (PEG-4000) is added, the precipitate is removed by centrifugation to obtain a supernatant, and 20%-30% (w / v) polyethylene glycol (PEG-4000) is added to the obtained supernatant, and the precipitate is recovered by centrifugation; (4) Affinity chromatography: The heparin affinity column is first fully equilibrated with an equilibration solution, the precipitate obtained in step (3) is dissolved with the equilibration solution, and then filtered with a 0.45 μm filter element before loading. After loading, 40 column volumes of the equilibration solution are first used, then 15 column volumes of the washing buffer are used, and finally, the column is eluted with an elution buffer, and the eluate is collected; The formula of the equilibration solution in affinity chromatography is: 0.1-0.2M Tris-HCl, 0.01-0.02M trisodium citrate, 0.2-0.3M sodium chloride, pH 7.0-8.0, the formula of the washing buffer is: 0.1-0.2M Tris-HCl, 0.01-0.02M trisodium citrate, 0.3-0.4M sodium chloride, pH 7.0-8.0, the formula of the elution buffer is: 0.1-0.2M Tris-HCl, 0.01-0.02M trisodium citrate, 1.5-2.5M sodium chloride, pH 7.0-8.0; (5) Pasteurella virus inactivation: adding a stabilizer to the eluate obtained in step (4), adjusting the pH of the solution to 7.0-8.0, and placing the solution in an environment at 60° C. for 10 hours; The stabilizer formula is: 5%-10% sodium citrate, 1.5-2.5M sodium chloride, 50-60% (w / v) sorbitol, pH 7.0-8.0; (6) Affinity chromatography: The heparin affinity column was first fully equilibrated with an equilibration solution, and the feed solution obtained in step (5) was filtered through a 0.45 μm filter element and then loaded. After loading, 40 column volumes of the equilibration solution were first used, and then 15 column volumes of the washing buffer were used. Finally, the column was eluted with an elution buffer and the eluate was collected; (7) Ultrafiltration concentration: The eluate obtained in step (6) was concentrated using a 10KD ultrafiltration membrane, and then dialyzed 5-6 times with an equal volume of dialysate, and finally concentrated to a human antithrombin III titer of 50 IU / mL; The dialysate formula is: glycine: 1-4% (w / w), pH: 7.0-8.0, liquid temperature: room temperature; (8) Sterile filtration: Sterile filter the product using a 0.22 μm filter element; (9) Nano-membrane virus removal filtration: pre-filter with a 0.1 μm filter element, then filter with a 15 nm filter element for virus removal; (10) Packaging; (11) Freeze-drying: precooling, quick freezing, annealing, primary drying and secondary drying are performed to finally obtain human antithrombin III freeze-dried powder.
